A recent study indicates that individuals who stop using new GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass much more quickly than those who halt traditional lifestyle programs.
Research printed in a major medical journal demonstrates that while obese people often shed a large proportion of their body weight while undergoing treatment, the weight is regained at an estimated rate of nearly a kilo each month once they quit.
"Individuals using these treatments need to be cognizant of the potential of fast rebound weight gain when the medication ends," warns researcher Dr. Susan Jebb.
Such speed of regain implies a reversion to pre-treatment mass within about 18 months.
Analyzing Approaches
The study, which examined 37 of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with older methods.
The team emphasize that individuals who lose weight through diet and exercise generally have a more gradual creep back—perhaps 100 grams monthly—post-intervention.
Explaining the Fast Rebound
Doctors suggest the mode of action of the drugs accounts for the accelerated weight return.
These medications copy a natural hormone called GLP-1, which moderates feelings of fullness.
"Sustained high doses of the hormone concentrations several times higher than normal might result in the body to produce less of its endogenous hormone, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' means hunger is no longer kept in check, making overeating far more likely."
A Chronic Condition?
The NHS recommend the jabs for people with weight-linked health risks, accompanied by prescribed lifestyle changes.
Many experts argue that, due to the likelihood of weight regain, the treatment is often ongoing.
This perspective is reinforced by pharmaceutical companies, who note that the results "underscore the persistent character of obesity," akin to managing conditions like diabetes.
User Experiences
People who have discontinued the jabs describe a intense resurgence of appetite.
"It felt as if a switch that goes on and I was suddenly extremely hungry," recalled a patient.
The struggle is exacerbated if users have not adopted permanent lifestyle or habit modifications during treatment.
Growing Interest
Figures show that a significant number of adults in the UK have tried weight-loss jabs in the past year, with interest being substantial.
- Use is more common among women than men.
- The middle-aged age group shows the highest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
In conclusion, researchers stress that while these medications are potent tools for weight loss, they are not a standalone solution and long-term success likely depends on integrated lifestyle management.
